厄洛替尼治疗晚期非小细胞肺癌的临床研究

Clinical Study on Erlotinib in Treatment of Advanced Non-small Cell Lung Cancer

目的：对晚期非小细胞肺癌的临床治疗中应用厄洛替尼的临床治疗效果进行分析和介绍。方法选择我院在2012年12月-2014年12月收治的晚期非小细胞肺癌患者30例作为研究对象，采用厄洛替尼对患者进行治疗，对患者在服用该药物后的毒副反应和治疗效果等进行观察。结果在30例晚期非小细胞肺癌患者当中，出现疾病进展的患者共计有10例，病情稳定的患者为13例，部分缓解的患者共计有6例，完全缓解的患者1例，其中共有7例患者治疗有效，占到了23.33%的比例。患者在用药之后主要出现了皮疹、皮肤瘙痒、腹泻以及恶心呕吐等毒副反应，程度均较轻，在采用对症治疗之后，患者的毒副反应得到有效缓解。结论采用厄洛替尼治疗晚期非小细胞肺癌患者具有明显的疗效，具有较为轻微的毒副反应。

Objective To study and introduce the clinical treatment effect of Erlotinib in treatment of advanced non-small cell lung cancer. Methods 30 patients with advanced non-small cell lung cancer in our hospital from December 2012 to December 2014 were selected as the research object,were treated with erlotinib,the toxic and side effect and therapeutic efficacy were observed. Results There were 10 progressive disease cases,13 stable disease cases,6 partial remission cases,1 complete remission case among 30 patients with advanced non-small cell lung cancer,there were 7 patients with effective treatment,accounted for 23.33% of the 30 cases. Conclusion The curative effect of erlotinib in the treatment of advanced non-small cell lung cancer is obvious,and the toxic and side effect is mild.